Results 31 to 40 of about 244,635 (318)

Tailoring CD19xCD3-DART exposure enhances T-cells to eradication of B-cell neoplasms. [PDF]

, 2018
Many patients with B-cell malignancies can be successfully treated, although tumor eradication is rarely achieved. T-cell-directed killing of tumor cells using engineered T-cells or bispecific antibodies is a promising approach for the treatment of ...
Aliberti S, Bareja R, Bonvini E, Bruna R, Brusa D, Chiaretti S, Chichili GR, Cignetti A, Circosta P, Deaglio S, Elemento O, Elia AR, Foà R, Giacomo FD, Gottardi D, Guarini AR, Inghirami G., Johnson S, Kyriakides PW, Landra I, Machiorlatti R, Massaia M, Monteleone E, Moore PA, Todaro M   +24 more
core   +1 more source

2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management

American journal of hematology/oncology, 2021
Diffuse large B cell lymphoma (DLBCL), the most common type of Non‐Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment.
Sandra Susanibar-Adaniya, S. Barta
semanticscholar   +1 more source

Primary diffuse large B-cell lymphoma of the uterus

Medicine, 2021
Uterine diffuse large B-cell lymphoma (DLBCL) is a rare clinical condition. Most studies for uterine DLBCL are derived from case reports and series.
Allyne M. Ensor, C. G. Sanchez, J. Ensor, K. Anand   +3 more
semanticscholar   +1 more source

Detection and outcome of occult leptomeningeal disease in diffuse large B-cell lymphoma and Burkitt lymphoma

Haematologica, 2014
The benefit of intrathecal therapy and systemic rituximab on the outcome of diffuse large B-cell lymphoma at risk of central nervous system disease is controversial.
Wyndham H. Wilson, Jacoline E.C. Bromberg, Maryalice Stetler-Stevenson, Seth M. Steinberg, Lourdes Martin-Martin, Carmen Muñiz, Juan Manuel Sancho, Maria Dolores Caballero, Marjan A. Davidis, Rik A. Brooimans, Blanca Sanchez-Gonzalez, Antonio Salar, Eva González-Barca, Jose Maria Ribera, Margaret Shovlin, Armando Filie, Kieron Dunleavy, Thomas Mehrling, Michele Spina, Alberto Orfao   +19 more
doaj   +1 more source

Dramatic radiotherapy response in a necrotic lymphoma mass: a case report

Journal of Medical Case Reports, 2020
Background Diffuse large B-cell lymphoma (DLBCL) represents the most common form of non-Hodgkin lymphoma and is characterized by an aggressive natural history. It often presents with rapid symptom development and disease progression.
Nicholas McNeil, Peter Gorayski, Danielle Blunt, Daniel Roos   +3 more
doaj   +1 more source

Two Cases of Pelvic Diffuse Large B-Cell Lymphoma

Journal of Investigative Medicine High Impact Case Reports, 2022
Primary diffuse large B-cell lymphoma presenting as an extranodal site in the pelvis is rare and can mimic a gynecological malignancy. Although management for diffuse large B-cell lymphoma is standardized and curative, prognosis depends on timely ...
Rupam Sharma MD, Arash Heidari MD, Everardo Cobos MD, Greti Petersen MD, Amin A. Ramzan MD, Rahul D. Polineni MD   +5 more
doaj   +1 more source

Consequences of the recurrent MYD88 L265P somatic mutation for B cell tolerance [PDF]

, 2014
MYD88L265P has recently been discovered as an extraordinarily frequent somatic mutation in benign monoclonal IgM gammopathy, Waldenström's macroglobulinemia, and diffuse large B cell lymphoma.
Beutler, Bruce, Goodnow, Christopher, Horikawa, Keisuke, Jeelall, Yogeshraj, Wang, James   +4 more
core   +1 more source

SnapShot: Diffuse Large B Cell Lymphoma

Cancer Cell, 2014
Diffuse large B cell lymphoma (DLBCL) is the most prevalent non-Hodgkin lymphoma (NHL) in adulthood, comprising 30%–40% of all new diagnoses. This aggressive disease can arise de novo or, less frequently, from the clinical evolution of various indolent B cell malignancies. While durable remissions can be achieved in a substantial proportion of cases by
PASQUALUCCI, Laura, Dalla Favera R.
openaire   +3 more sources

LINC00908 Promotes Diffuse Large B-Cell Lymphoma Development by Down-Regulating miR-671-5p

Cancer Management and Research, 2021
Hong Zeng, Yongqiang Wei, Xiaolei Wei, Ru Feng Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, People’s Republic of ChinaCorrespondence: Ru FengDepartment of Hematology, Nanfang Hospital, Southern ...
Zeng H, Wei Y, Wei X, Feng R
doaj  

JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms. [PDF]

, 2016
JMJD3 (Jumonji domain containing-3), a histone H3 Lys27 (H3K27) demethylase, has been reported to be involved in the antigen-driven differentiation of germinal center B-cells.
Bai, Nan, Han, Jihong, Li, Luyuan, Luo, Yunping, Ren, Guosheng, Shen, Long, Stupack, Dwayne G, Tan, Xiaoyue, Xiang, Rong, Xun, Jing, Zhang, Yan   +10 more
core   +1 more source